Kick back and consider this: evidence is thin for medical cannabis across most conditions it’s used to treat. A comprehensive UCLA Health–led review in JAMA finds that for many issues—like chronic pain, anxiety, and insomnia—the science just isn’t strong enough to back widespread use.
The analysis sifted through over 2,500 articles published from January 2010 to September 2025, including randomized trials, meta-analyses, and clinical guidelines. Of these, more than 120 high-priority studies were highlighted based on their large sample sizes, recency, topic relevance, and overall significance. This comes at a time when cannabis and cannabinoids like CBD are increasingly popular, with about 27% of people in the U.S. and Canada reporting usage for pain, anxiety, sleep, or related concerns in a 2018 survey.
Dr. Michael Hsu of UCLA Health, the study’s first author, points out a gap between public perception and the latest scientific evidence. He notes that many people seek cannabis for relief, but the review shows notable mismatches between what the public believes and what science supports regarding its effectiveness for most conditions. Clinician guidance is crucial for safe, evidence-based conversations with patients.
The review did confirm a defined, FDA-approved role for pharmaceutical-grade cannabinoids, but only in a narrow set of conditions. These include HIV/AIDS-related appetite loss, chemotherapy-induced nausea and vomiting, and certain severe pediatric epilepsy syndromes such as Dravet syndrome and Lennox-Gastaut syndrome.
For most other conditions, the evidence remains inconclusive or lacking. Even though more than half of medical cannabis users report chronic pain as their reason for use, current clinical guidelines do not endorse cannabis-based medicines as a first-line treatment for chronic pain.
Health risks associated with cannabis use were also highlighted. Longitudinal data suggest that high-potency cannabis among adolescents may be linked to higher rates of psychotic symptoms and generalized anxiety disorder compared with lower-potency products. Approximately 29% of medical cannabis users meet criteria for cannabis use disorder. Daily use—especially inhaled or high-potency products—might be tied to cardiovascular risks, including higher rates of coronary heart disease, heart attack, and stroke versus non-daily use.
The authors urge clinicians to screen for cardiovascular disease and psychotic disorders, review potential drug interactions, and weigh risks against benefits before recommending THC-containing products for medical purposes. As Dr. Hsu states, patients deserve transparent conversations about what the science can and cannot confirm.
Several study limitations are acknowledged. The paper is not a systematic review and did not perform a formal risk-of-bias assessment for included studies. Many studies were observational and could be subject to confounding. Additionally, trial findings may not generalize to every patient due to differences in study design, patient characteristics, and the cannabis products tested.
Looking ahead, the authors call for more rigorous research to better delineate benefits and risks and to provide clearer clinical guidance that can improve patient care. The study team includes researchers from Harvard, UC San Francisco, Washington University School of Medicine, and New York University.
